title: Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
abstract: OBJECTIVE
  The aim of this study was to evaluate the 2-year survival rate in a group of women in complete clinical remission (cCR) from Stage III ovarian cancer following front-line therapy who were then treated with a 6-month course of altretamine.
  
  
  METHODS
  Patients were documented to be in cCR by physical examination, computed tomography or magnetic resonance imaging scan, and serum CA-125. Treatment consisted of altretamine (Hexalen) 260 mg/m(2)/day po divided into four doses taken after meals and at bedtime for 14 of 28 days for six cycles. Based on previous experience in the Southwest Oncology Group, the treatment would be considered promising if the 2-year survival rate was > or = 65% as measured from study registration.
  
  
  RESULTS
  From 9/1/93 and 7/1/97, 112 patients were registered and 97 were fully evaluable. The majority of patients had optimally debulked (< or = 1 cm: 63%), high-grade (Grade 3: 82%) tumors. The 2-year survival rate in this study was 75% (95% CI: 66-84%). For those patients with optimal disease, the 2-year survival rate was 82% (95% CI: 72-92%) and for those with suboptimal disease it was 64% (95% CI: 48-79%). Four patients (4%) experienced Grade 4 and 21 patients (22%) experienced Grade 3 toxicities consisting primarily of nausea/vomiting, neutropenia, fatigue, anxiety, and paresthesias.
  
  
  CONCLUSIONS
  The 2-year survival rate in this study warrants further evaluation of consolidation therapy for women in clinical complete remission following front-line chemotherapy for Stage III ovarian cancer. Caution is advised in the interpretation of these data, however, because of the nonrandomized nature of the trial and the unknown contribution of front-line use of paclitaxel to the durability of clinical complete response.
authors.affiliation: Vanderbilt University Medical Center, Nashville, Tennessee 37232-5536, USA.
authors.forename: M L
authors.initials: ML
authors.lastname: Rothenberg
authors.forename: P Y
authors.initials: PY
authors.lastname: Liu
authors.forename: S
authors.initials: S
authors.lastname: Wilczynski
authors.forename: E V
authors.initials: EV
authors.lastname: Hannigan
authors.forename: S A
authors.initials: SA
authors.lastname: Weiner
authors.forename: G R
authors.initials: GR
authors.lastname: Weiss
authors.forename: V J
authors.initials: VJ
authors.lastname: Hunter
authors.forename: J A
authors.initials: JA
authors.lastname: Chapman
authors.forename: A
authors.initials: A
authors.lastname: Tiersten
authors.forename: P C
authors.initials: PC
authors.lastname: Kohler
authors.forename: D S
authors.initials: DS
authors.lastname: Alberts
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006585:Altretamine / Q000009:adverse effects / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D018394:CA-125 Antigen / Q000097:blood; D004334:Drug Administration Schedule; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D017239:Paclitaxel / Q000627:therapeutic use; D012074:Remission Induction; D015996:Survival Rate
chemical_list: D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D018394:CA-125 Antigen; D017239:Paclitaxel; D006585:Altretamine